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ABSTRACT
Background CheckMate 9KD (NCT03338790) is a non-
randomized, multicohort, phase 2 trial of nivolumab plus
other anticancer treatments for metastatic castration-
resistant prostate cancer (mCRPC). We report results
from cohorts A1 and A2 of CheckMate 9KD, specifically
evaluating nivolumab plus rucaparib.
Methods CheckMate 9KD enrolled adult patients with
histologically confirmed mCRPC, ongoing androgen deprivation
therapy, and an Eastern Cooperative Oncology Group
performance status of 0–1. Cohort A1 included patients with
postchemotherapy mCRPC (1–2 prior taxane-based regimens)
and ≤2 prior novel hormonal therapies (eg, abiraterone,
enzalutamide, apalutamide); cohort A2 included patients
with chemotherapy-naïve mCRPC and prior novel hormonal
therapy. Patients received nivolumab 480 mg every 4 weeks
plus rucaparib 600 mg two times per day (nivolumab dosing ≤2
years). Coprimary endpoints were objective response rate
(ORR) per Prostate Cancer Clinical Trials Working Group 3 and
prostate-specific antigen response rate (PSA50-RR; ≥50% PSA
reduction) in all-treated patients and patients with homologous
recombination deficiency (HRD)-positive tumors, determined
before enrollment. Secondary endpoints included radiographic
progression-free survival (rPFS), overall survival (OS), and
safety.
Results Outcomes (95% CI) among all-treated, HRD-
positive, and BRCA1/2-positive populations for cohort
A1 were confirmed ORR: 10.3% (3.9–21.2) (n=58),
17.2% (5.8–35.8) (n=29), and 33.3% (7.5–70.1) (n=9);
confirmed PSA50-RR: 11.9% (5.9–20.8) (n=84), 18.2%
(8.2–32.7) (n=44), and 41.7% (15.2–72.3) (n=12); median
rPFS: 4.9 (3.7–5.7) (n=88), 5.8 (3.7–8.4) (n=45), and
5.6 (2.8–15.7) (n=12) months; and median OS: 13.9
(10.4–15.8) (n=88), 15.4 (11.4–18.2) (n=45), and 15.2
(3.0–not estimable) (n=12) months. For cohort A2 they
were confirmed ORR: 15.4% (5.9–30.5) (n=39), 25.0%
(8.7–49.1) (n=20), and 33.3% (7.5–70.1) (n=9); confirmed
PSA50-RR: 27.3% (17.0–39.6) (n=66), 41.9 (24.5–60.9)
(n=31), and 84.6% (54.6–98.1) (n=13); median rPFS:
8.1 (5.6–10.9) (n=71), 10.9 (6.7–12.0) (n=34), and
10.9 (5.6–12.0) (n=15) months; and median OS: 20.2

WHAT IS ALREADY KNOWN ON THIS TOPIC
⇒ Efficacy of single-agent immunotherapy for patients

with metastatic castration-resistant prostate cancer
(mCRPC) has been suboptimal, leading to the recent
investigation of combination therapy approaches for
this patient population.

WHAT THIS STUDY ADDS
⇒ Nivolumab plus rucaparib has clinical activity in patients

with homologous recombination deficiency-
positive
mCRPC, particularly those harboring BRCA1/2 mutations, with an acceptable safety profile.

HOW THIS STUDY MIGHT AFFECT RESEARCH,
PRACTICE OR POLICY
⇒ These results contribute to our understanding of the

efficacy and safety of combined PD-1/PD-L1 and
poly(ADP-ribose) polymerase inhibition for postchemotherapy and chemotherapy-naïve mCRPC.

(14.1–22.8) (n=71), 22.7 (14.1–not estimable) (n=34),
and 20.2 (11.1–not estimable) (n=15) months. In cohorts
A1 and A2, respectively, the most common any-grade
and grade 3–4 treatment-related adverse events (TRAEs)
were nausea (40.9% and 40.8%) and anemia (20.5% and
14.1%). Discontinuation rates due to TRAEs were 27.3%
and 23.9%, respectively.
Conclusions Nivolumab plus rucaparib is active
in patients with HRD-positive postchemotherapy or
chemotherapy-naïve mCRPC, particularly those harboring
BRCA1/2 mutations. Safety was as expected, with no
new signals identified. Whether the addition of nivolumab
incrementally improves outcomes versus rucaparib alone
cannot be determined from this trial.
Trial registration number NCT03338790.

BACKGROUND
Over the past two decades, therapeutic
advances have improved outcomes for
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patients with metastatic castration-
resistant prostate
cancer (mCRPC), with the approval of various chemotherapies, hormonal therapies, poly(ADP-
ribose) polymerase (PARP) inhibitors, and the immunotherapy
sipuleucel-T.1–3 Despite the emergence of these treatment
options, mCRPC remains an incurable, fatal malignancy;
thus, additional therapeutic strategies continue to be
evaluated.
One such strategy, investigated in several clinical trials,
involves combining immune checkpoint inhibitors with
other anticancer treatments that have the potential to
stimulate an increasingly immune-
responsive prostate
cancer microenvironment, testing the hypothesis that
the immunotherapeutic effects will be augmented and
outcomes improved.4–7 This combination approach is
necessary because treatment with single-agent immune
checkpoint inhibitors targeting the anti-
programmed
death-
1 (PD-
1)/programmed death ligand 1 (PD-
L1)
pathway does not appear to elicit clinically impactful antitumor responses in unselected mCRPC populations.8–11
Although pivotal trials of ipilimumab (a cytotoxic
T-
lymphocyte antigen-
4 checkpoint inhibitor) monotherapy originally failed to show improvements in overall
survival (OS) versus placebo for unselected patients
with mCRPC,12 13 an excess of long-term survivors versus
placebo has since been reported in this clinical setting.14
Preliminary studies of nivolumab combined with ipilimumab have shown clinical activity in patients with
mCRPC,15 16 supporting the concept of immunotherapy-
based combinatorial strategies for this patient population.
PARP inhibitors have demonstrated encouraging clinical activity in patients with mCRPC who carry alterations
in DNA damage repair genes, including those associated
with homologous recombination deficiency (HRD),17–19
leading to regulatory approvals in Europe and the United
States. For example, one such PARP inhibitor, rucaparib,
has shown antitumor activity as monotherapy for postchemotherapy mCRPC in the TRITON2 trial, with a
reported objective response rate (ORR) per independent
radiology review of 43.5% and a prostate-specific antigen
(PSA) response rate of 54.8% among patients harboring
deleterious BRCA1 or BRCA2 mutations.19 PARP inhibitors act by further limiting DNA damage repair in tumor
cells that carry DNA damage repair mutations, resulting
in tumor cell death; this produces tumor neoantigens
and increases immunogenicity, thus promoting a more
immune-
responsive tumor microenvironment.20 21
Indeed, in preclinical studies across various tumor types,
PARP inhibitors have been shown to synergize with PD-1/
PD-
L1 checkpoint blockade and potentiate antitumor
efficacy.22–25 As such, there is a compelling therapeutic
rationale for clinical investigations into the combination
of immune checkpoint inhibitors and PARP inhibitors for
patients with mCRPC.
Here, we report final analysis results from cohorts A1
and A2 of the multicohort, phase 2 CheckMate 9KD trial,
which evaluated the efficacy and safety of the anti-PD-1
immune checkpoint inhibitor nivolumab combined with
2

rucaparib in men with either chemotherapy-
naïve or
postchemotherapy mCRPC.

METHODS
Study design and participants
CheckMate 9KD is a non-randomized, open-label, multicohort, phase 2 trial of nivolumab combined with rucaparib (cohorts A1 and A2), docetaxel (cohort B), or
enzalutamide (cohort C) for mCRPC. Methods for the
overall study and specific to cohort B have previously
been described.26 In brief, the CheckMate 9KD study
population comprises adult patients (≥18 years of age)
with histological confirmation of adenocarcinoma of
the prostate with radiologic evidence of stage IV disease
(N1 and/or M1), ongoing androgen deprivation therapy
or bilateral orchiectomy (confirmed by testosterone
level ≤1.73 nmol/L at screening), and documented
progressive disease per Prostate Cancer Clinical Trials
Working Group 3 (PCWG3) criteria. Eligible patients were
also required to have an Eastern Cooperative Oncology
Group performance status of 0 or 1 and sufficient tumor
tissue obtained within 5 years before enrollment from a
metastatic or primary tumor lesion not previously irradiated. Exclusion criteria included active brain metastases,
conditions requiring systemic treatment with corticosteroids (>10 mg daily prednisone equivalent) or other
immunosuppressive medications within 14 days of start of
study treatment, and prior therapy specifically targeting
T-cell costimulation or immune checkpoint pathways.
Cohort assignment was based on prior systemic treatresistant setting and
ment received in the castration-
eligibility to begin immediate chemotherapy. For assignment to cohort A1, patients must have received 1–2 prior
taxane-based chemotherapy regimens in the castration-
resistant setting, and prior treatment with up to two novel
hormonal therapies (eg, abiraterone, enzalutamide, or
apalutamide) for castration-resistant disease was allowed.
For assignment to cohort A2, patients must have been
chemotherapy-
naïve for mCRPC, have received prior
abiraterone, enzalutamide, and/or apalutamide for
castration-resistant disease up to 28 days before cohort
assignment, and not be candidates for or have refused
immediate chemotherapy. Although patients were
excluded from cohort A2 if they had received prior chemotherapy for mCRPC, prior treatment with docetaxel for
metastatic hormone-sensitive prostate cancer was allowed
if at least 12 months had elapsed from the last dose.
Patients in cohort A2 were also required to be asymptomatic or minimally symptomatic according to the Brief Pain
Inventory-Short Form performed at screening. Patients
were excluded from both cohorts A1 and A2 if they had
myelodysplastic syndrome/acute myeloid leukemia,
gastrointestinal disorders likely to interfere with absorption of study treatment, and/or had received previous
treatment with a PARP inhibitor, mitoxantrone, cyclophosphamide, or platinum-based chemotherapy.
Fizazi K, et al. J Immunother Cancer 2022;10:e004761. doi:10.1136/jitc-2022-004761
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Treatment
Patients in cohorts A1 and A2 received a combination
of intravenous nivolumab 480 mg every 4 weeks and oral
rucaparib 600 mg two times per day. Nivolumab dosing
was limited to at most 2 years from the date of first
nivolumab dose in the absence of disease progression;
rucaparib was administered continuously until disease
progression. Treatment with either nivolumab or rucaparib could also be prematurely discontinued due to
unacceptable toxicity, withdrawal of patient consent, or
the end of the trial, whichever occurred first.
Endpoints and assessments
As previously described,26 the co-primary endpoints for
CheckMate 9KD were ORR (defined as the proportion
of patients achieving a confirmed complete or partial
response as assessed by the investigator using PCWG3
criteria) and PSA response rate (PSA50-RR; defined as
the proportion of patients with a ≥50% decrease in PSA
from baseline). Secondary endpoints included time to
and duration of objective response, time to PSA progression, investigator-assessed radiographic progression-free
survival (rPFS), OS, and safety. Time to and duration of
objective response, time to PSA progression, and rPFS
were evaluated using PCWG3 criteria. For cohorts A1
and A2, all efficacy endpoints were assessed prospectively
in the all-
treated population (all patients receiving at
least one dose of nivolumab and/or rucaparib) and in
subgroups based on HRD status (positive versus negative/
not evaluable). As previously described,26 HRD status was
determined before cohort assignment using the validated
next-generation sequencing-based FoundationOne CDx
and FoundationACT tests (Foundation Medicine Inc,
Cambridge, MA, USA) for tissue-based and plasma-based
assessment, respectively. HRD positivity from tissue was
defined as the presence of a gene alteration that included
protein truncating mutations, protein truncating rearrangements, splice site mutations, homozygous deletions, or deleterious missense mutations in ATM, BARD1,
BRCA1, BRCA2, BRIP1, CDK12, CHEK2, FANCA, NBN,
PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L.
HRD positivity from plasma was defined as the presence
of a gene alteration that included protein truncating
mutations, protein truncating rearrangements, splice site
mutations, or deleterious missense mutations in ATM,
BRCA1, BRCA2, CDK12, CHEK2, or PALB2. All testing
for HRD was performed within Foundation Medicine
Inc’s College of American Pathologists-accredited, Clinical Laboratory Improvement Amendments-
certified
laboratory. A patient was considered HRD-
positive if
one of the two assays described (tissue based or plasma
based) detected an alteration as defined above. Objective responses and related endpoints were determined
only in patients with measurable disease at baseline; PSA
responses and related endpoints were determined only in
patients with a baseline and at least one postbaseline PSA
assessment (PSA-evaluable patients).
Fizazi K, et al. J Immunother Cancer 2022;10:e004761. doi:10.1136/jitc-2022-004761

Post hoc exploratory endpoints included the time to
and duration of PSA response, and associations between
efficacy outcomes and specific HRD-related genetic alterations or tumor mutational burden (TMB). TMB was
measured using the FoundationOne CDx assay (Foundation Medicine, Cambridge, MA, USA), counting all
synonymous and nonsynonymous mutations present
within 1.1 Mb of coding genome and filtering out potential germline variants. Analyses were conducted based on
the median TMB for all treated patients with available
TMB data across all cohorts in the CheckMate 9KD trial,
which was 6.7 mutations per Mb.
Adverse events (AEs), graded per National Cancer Institute Common Terminology Criteria for Adverse Events
V.4.03, were assessed continuously and are reported from
first dose of nivolumab plus rucaparib up to 30 days after
last dose of study drug. Treatment-related AEs (TRAEs)
were defined as events considered by the investigator to
be related to any study treatment (ie, nivolumab, rucaparib, or both); no data are available on assignment of
an event to a specific treatment. For CheckMate 9KD,
immune-
mediated AEs (ie, events consistent with an
immune-mediated mechanism or component for which
noninflammatory etiologies were excluded, eg, infection
or tumor progression) are reported from first dose up to
100 days after last dose of study drug.26
As outlined in the prior publication from this study,26
assessment of tumors by CT or MRI and radionuclide
bone scans were performed at screening, every 8 weeks
(±7 days) after the first dose for the first 24 weeks, then
every 12 weeks (±7 days) until disease progression or treatment discontinuation (whichever occurred later). Objective responses and progressive disease were confirmed by
repeat scans. For cohorts A1 and A2, PSA was assessed
locally at screening, on day 1 of cycles 1–4, then on day 1
of every subsequent even-numbered cycle (cycle 6, cycle 8,
cycle 10, etc). PSA responses were confirmed by a second
consecutive assessment performed at least 3 weeks later.
Statistical analyses
Planned sample sizes for cohorts A1 and A2 were calculated using the precision approach for the dual primary
endpoints with respective planned enrollment of 48
and 60 patients with baseline measurable disease evaluable for ORR and 80 and 100 patients evaluable for
PSA50-
RR. Power calculations were assessed for each
primary endpoint using the one-
cohort binomial test,
with the planned number of treated patients expected
to provide adequate power for detecting an increase
of 15% in ORR and an increase of 10% in PSA50-RR
compared with standard-
of-
care reference rates. Estimates of reference ORR and PSA response rates are
described in online supplemental methods 1. Response
rates and corresponding two-sided exact 95% CIs were
calculated using Clopper–Pearson methodology.27 The
Kaplan-Meier method was used to estimate time to and
duration of objective response, time to PSA progression,
rPFS, and OS.28 Median values and corresponding 95%
3
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Table 1 Baseline demographic and clinical characteristics in cohorts A1 and A2
Cohort A1
(postchemotherapy) (N=88)

Cohort A2
(chemotherapy-naïve) (N=71)

Median age (range), years
Age categories, n (%)

66 (46–85)

73 (51–87)

 <70 years
 ≥70 years

53 (60.2)
35 (39.8)

29 (40.8)
42 (59.2)

72 (81.8)
4 (4.5)
2 (2.3)
10 (11.4)

64 (90.1)
1 (1.4)
1 (1.4)
5 (7.0)

33 (37.5)
38 (43.2)
17 (19.3)

22 (31.0)
28 (39.4)
21 (29.6)

39 (44.3)
48 (54.5)
1 (1.1)

30 (42.3)
41 (57.7)
0

 ≤7
 >7
 Not reported

24 (27.3)
60 (68.2)
4 (4.5)

29 (40.8)
39 (54.9)
3 (4.2)

Median time since diagnosis (range), years

5.2 (1.1–25.1)

4.1 (0.4–19.6)

7 (8.0)
17 (19.3)
63 (71.6)
1 (1.1)

9 (12.7)
13 (18.3)
46 (64.8)
3 (4.2)

 Yes
 No
 Not reported

30 (34.1)
56 (63.6)
2 (2.3)

17 (23.9)
48 (67.6)
6 (8.5)

Measurable disease, n (%)

58 (65.9)

39 (54.9)

 <4
 ≥4
 Not reported

66 (75.0)
19 (21.6)
3 (3.4)

57 (80.3)
13 (18.3)
1 (1.4)

Median PSA (range), ng/mL

95.8 (0.1–4816.0)

37.8 (0.6–5807.0)

45 (51.1)
40 (45.5)
3 (3.4)

34 (47.9)
36 (50.7)
1 (1.4)

22 (25.0)
66 (75.0)

11 (15.5)
60 (84.5)

 <1.5 × ULN
 ≥1.5 × ULN

66 (75.0)
22 (25.0)

57 (80.3)
14 (19.7)

Prior cancer surgery, n (%)
Prior radiotherapy, n (%)

42 (47.7)
57 (64.8)

30 (42.3)
35 (49.3)

Characteristic

Race, n (%)
 White
 Black or African American
 Asian
 Other
Geographic region, n (%)
 Europe
 Rest of the world*
 USA
ECOG PS, n (%)
 0
 1
 Not reported
Gleason score, n (%)

Bone lesions, n (%)
 0
 1–4
 >4
 Not reported
Visceral metastases, n (%)

Average daily worst pain intensity, n (%)

HRD status, n (%)
 Positive
 Negative
 Not evaluable†
Hemoglobin, n (%)
 <110 g/L
 ≥110 g/L
Alkaline phosphatase, n (%)

Continued
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Table 1 Continued
Cohort A1
(postchemotherapy) (N=88)

Cohort A2
(chemotherapy-naïve) (N=71)

 1
 2

62 (70.5)
26 (29.5)

0
0

Prior novel hormonal therapy, n (%)
 Abiraterone only
 Enzalutamide only
 Abiraterone and enzalutamide

65 (73.9)
19 (21.6)‡
19 (21.6)
27 (30.7)

70 (98.6)§
43 (60.6)
17 (23.9)§
10 (14.1)

Characteristic
Prior taxane chemotherapy regimens in the castration-
resistant setting, n (%)

*Represents Australia, Canada and South America.
†Represents patients with missing values for HRD using the assays described in the Methods section; reasons for missing values include, for
example, missing or inadequate sample material or methodology/assay failures.
‡Notification of prior treatment with apalutamide in one patient recorded as receiving abiraterone alone was received after database lock; in
total 18 patients (20.5%) in cohort A1 received prior abiraterone alone and one patient (1.1%) received prior treatment with both abiraterone
and apalutamide.
§Notification of prior treatment with enzalutamide in one additional patient was received after database lock; in total 18 patients (25.4%) in
cohort A2 received prior enzalutamide alone and all 71 (100.0%) received prior treatment with 1–2 novel hormonal therapies per protocol.
ECOG PS, Eastern Cooperative Oncology Group performance status; HRD, homologous recombination deficiency; PSA, prostate-specific
antigen; ULN, upper limit of normal.

CIs for duration of objective response, rPFS, and OS were
constructed based on a log-log transformed CI for the
survivor function.29
RESULTS
Patients
Overall, 88 and 71 eligible patients with mCRPC received
treatment with nivolumab plus rucaparib in cohorts A1
and A2, respectively. Baseline demographic and clinical
characteristics are shown in table 1.
In cohorts A1 and A2, respectively, median age (range)
was 66 (46–85) and 73 (51–87) years, 30 (34.1%) and 17
(23.9%) patients had visceral metastases, 58 (65.9%) and
39 (54.9%) had measurable disease at baseline, and 45
(51.1%) and 34 (47.9%) had HRD-positive tumors. Per
the cohort-specific inclusion criteria, all 88 patients in
cohort A1 had received one or two prior taxane-based
chemotherapy regimens (docetaxel and/or cabazitaxel); 62 (70.5%) had received one prior regimen and
26 (29.5%) had received two prior regimens. Of the
26 patients receiving two prior taxane-
based chemotherapy regimens, two had not received a prior novel
hormonal therapy, 11 had also received one prior novel
hormonal therapy, and 13 had also received two prior
novel hormonal therapies. Patient disposition is shown
in online supplemental table 1; at database lock (July 17,
2020, for cohort A1; March 12, 2021, for cohort A2), 83
(94.3%) patients in cohort A1 and 65 (91.5%) patients
in cohort A2 had discontinued all study treatment,
mostly because of disease progression (65 (73.9%) and
43 (60.6%) patients, respectively) or study drug toxicity
(9 (10.2%) and 8 (11.3%) patients, respectively). One
patient in cohort A1 (1.1%) and one in cohort A2 (1.4%)
discontinued due to death.
Fizazi K, et al. J Immunother Cancer 2022;10:e004761. doi:10.1136/jitc-2022-004761

Study drug exposure
Overall median duration of nivolumab plus rucaparib
combination therapy (range) was 4.4 (0.3–17.9) months
in cohort A1 and 5.8 (0.1–30.9) months in cohort A2.
Treatment exposure data for the individual components
are summarized in online supplemental table 2. Median
duration of treatment (range) for nivolumab was 3.7 (0.0–
17.8) months in cohort A1 and 4.6 (0.0–23.2) months in
cohort A2, and for rucaparib was 4.0 (0.3–17.9) months
in cohort A1 and 5.5 (0.0–30.9) months in cohort A2.
The median number of administered nivolumab doses
(range) was 4.5 (1–19) and 6.0 (1–25) in cohorts A1 and
A2, respectively. Median duration of follow-up was 11.9
and 17.5 months, respectively.
Efficacy, cohort A1 (postchemotherapy)
Among 58 treated patients with baseline measurable
disease in cohort A1, the confirmed ORR (95% CI) was
10.3% (3.9% to 21.2%), comprising six patients who
achieved partial responses (table 2). Median time to
objective response (range) was 1.9 (1.6–3.7) months
and median duration of objective response (95% CI) was
6.5 (3.5 to not estimable) months. In 84 PSA-evaluable
patients, the confirmed PSA50-
RR (95% CI) was 11.9%
(5.9% to 20.8%; table 2). Median time to PSA response
(range) was 1.0 (0.9–3.0) month and median duration
of PSA response (95% CI) was 6.6 (5.6 to 9.5) months.
Median time to PSA progression (95% CI) was 3.8 (2.8
to 6.5) months. In all 88 treated patients, median rPFS
(95% CI) was 4.9 (3.7 to 5.7) months (figure 1A) and
median OS (95% CI) was 13.9 (10.4 to 15.8) months
(figure 1B).
The confirmed ORR (95% CI) among subpopulations of patients in cohort A1 with baseline measurable
disease and HRD-positive (n=29) versus HRD-negative/
5
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29.5 (16.8 to 45.2)

11.9 (5.9 to 20.8)
19.0 (11.3 to 29.1)

 Confirmed or unconfirmed
 PSA50-RR (95% CI), %

7.5 (1.6 to 20.4)

5.0 (0.6 to 16.9)

40

0
1 (3.4)
15 (51.7)
13 (44.8)
0

3.4 (0.1 to 17.8)

29

31.8 (20.9 to 44.4)

27.3 (17.0 to 39.6)

66

0
6 (15.4)
26 (66.7)
5 (12.8)
2 (5.1)

15.4 (5.9 to 30.5)

39

HRD-negative/not evaluable Overall

48.4 (30.2 to 66.9)

41.9 (24.5 to 60.9)

31

0
5 (25.0)
11 (55.0)
3 (15.0)
1 (5.0)

25.0 (8.7 to 49.1)

20

HRD-positive

Cohort A2 (chemotherapy-naïve)
(N=71)

17.1 (6.6 to 33.6)

14.3 (4.8 to 30.3)

35

0
1 (5.3)
15 (78.9)
2 (10.5)
1 (5.3)

5.3 (0.1 to 26.0)

19

HRD-negative/not evaluable

*Confirmed complete or partial response per PCWG3.
†Patients with measurable disease at baseline.
‡A decrease in PSA from baseline to the lowest postbaseline PSA result of ≥50%; a second consecutive value obtained at least 3 weeks later was required for confirmation of PSA responses.
§Patients with a baseline and at least one postbaseline PSA assessment.
BOR, best overall response; HRD, homologous recombination deficiency; ORR, objective response rate; PCWG3, Prostate Cancer Clinical Trials Working Group 3; PSA, prostate-specific antigen; PSA50-
RR, PSA response rate.

18.2 (8.2 to 32.7)

84

 Confirmed PSA50-RR (95% CI), %

44

0
5 (17.2)
16 (55.2)
5 (17.2)
3 (10.3)

17.2 (5.8 to 35.8)

29

HRD-positive

 Evaluable patients, n§

PSA response‡

 Complete response
 Partial response
 Stable disease
 Progressive disease
 Unable to determine
0
6 (10.3)
31 (53.4)
18 (31.0)
3 (5.2)

10.3 (3.9 to 21.2)

 Confirmed ORR (95% CI), %

 BOR, n (%)

58

 Evaluable patients, n†

Overall

Cohort A1 (postchemotherapy)
(N=88)

Objective and PSA response outcomes in cohort A1 and A2

Objective response*

Table 2
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(n=44) versus HRD-
negative/not evaluable (n=40)
tumors was 18.2% (8.2% to 32.7%) versus 5.0% (0.6% to
16.9%; table 2). Among all treated patients in cohort A1
with HRD-positive (n=45) versus HRD-negative/not evaluable (n=43) tumors, median rPFS (95% CI) was 5.8 (3.7
to 8.4) versus 3.7 (1.8 to 5.5) months, and median OS
(95% CI) was 15.4 (11.4 to 18.2) versus 9.4 (7.2 to 14.7)
months (figure 1A,B).
Efficacy, cohort A2 (chemotherapy-naïve)
Among 39 treated patients with baseline measurable
disease in cohort A2, the confirmed ORR (95% CI) was
15.4% (5.9% to 30.5%), comprising six patients who
achieved partial responses (table 2). Median time to
objective response (range) was 2.0 (1.8–11.0) months
and median duration of objective response (95% CI) was
7.1 (3.8 to not estimable) months. In 66 PSA-evaluable
patients, the confirmed PSA50-
RR (95% CI) was 27.3%
(17.0% to 39.6%; table 2). Median time to PSA response
(range) was 1.8 (0.9–7.3) months and median duration
of PSA response (95% CI) was 12.9 (4.1 to not estimable)
months. Median time to PSA progression (95% CI) was
3.5 (2.8 to 6.2) months. In all 71 treated patients, median
rPFS (95% CI) was 8.1 (5.6 to 10.9) months (figure 1C)
and median OS (95% CI) was 20.2 (14.1 to 22.8) months
(figure 1D).
The confirmed ORR (95% CI) among subpopulations of patients in cohort A2 with baseline measurable
disease and HRD-positive (n=20) versus HRD-negative/
not evaluable (n=19) tumors was 25.0% (8.7% to 49.1%)
versus 5.3% (0.1% to 26.0%), respectively (table 2). The
confirmed PSA50-RR (95% CI) among subpopulations of
PSA-evaluable patients in cohort A2 with HRD-positive
(n=31) versus HRD-
negative/not evaluable (n=35)
tumors was 41.9% (24.5% to 60.9%) versus 14.3% (4.8%
to 30.3%; table 2). Among all treated patients in cohort
A2 with HRD-positive (n=34) versus HRD-negative/not
evaluable (n=37) tumors, median rPFS (95% CI) was 10.9
(6.7 to 12.0) versus 5.6 (3.7 to 9.1) months, and median
OS (95% CI) was 22.7 (14.1 to not estimable) versus 19.0
(8.2 to 22.1) months (figure 1C,D).

Figure 1 Kaplan-Meier plots of rPFS and OS in all treated
patients and based on HRD status for cohort A1 (A,
B) and cohort A2 (C, D). HRD, homologous recombination
deficiency; NE, not evaluable; OS, overall survival; rPFS,
radiographic progression-free survival.

not evaluable (n=29) tumors was 17.2% (5.8% to 35.8%)
versus 3.4% (0.1% to 17.8%), respectively (table 2). The
confirmed PSA50-RR (95% CI) among subpopulations of
PSA-evaluable patients in cohort A1 with HRD-positive
Fizazi K, et al. J Immunother Cancer 2022;10:e004761. doi:10.1136/jitc-2022-004761

Biomarker analyses, cohorts A1 (postchemotherapy) and A2
(chemotherapy-naïve)
Data on specific HRD-
related genetic mutations were
available for 42 patients with HRD-
positive tumors in
cohort A1 and 33 patients with HRD-positive tumors in
cohort A2. In both cohorts, the most frequent mutations
were in the BRCA1/2 (n=12 and n=15, respectively) or
ATM (n=15 and n=9, respectively) genes, with the vast
majority being frameshift or truncating variants (online
supplemental figure 1).
Maximum changes in tumor size and PSA are shown
based on HRD gene mutation(s) in figures 2 and 3, with
related gene-
specific outcomes summarized in online
supplemental tables 3 and 4. The most noteworthy
response outcomes were observed in patients carrying
BRCA1/2 mutations. In cohort A1, among nine patients
7
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Figure 2 Waterfall plots of maximum change from baseline in tumor size (A) and PSA (B) based on HRD-related genetic
mutations for cohort A1. *Patients with a measurable target lesion at baseline and at least one on-treatment tumor assessment;
seven patients did not have available tumor change data. †Represents patients categorized as HRD-positive but with missing
information on the specific genetic mutation(s). ‡Patients with baseline PSA and at least one postbaseline PSA assessment.
Horizontal reference lines indicate a 30% reduction consistent with a PCWG3 response (A) or a 50% reduction consistent with
a PSA response (B). Open squares indicate truncation of percent change at +100%. +Symbol represents a confirmed objective
response; ▲ Symbol represents a confirmed PSA response. HRD, homologous recombination deficiency; MSI-H, microsatellite
instability-high; NA, not available; PCWG3, Prostate Cancer Clinical Trials Working Group 3; PSA, prostate-specific antigen.

with baseline measurable disease and BRCA1/2 mutations
(all BRCA2 alone), six (66.7%) had a ≥30% reduction in
target lesions, with three (33.3%) achieving a confirmed
objective response (figure 2A, table 3). Among 12 PSA-
evaluable patients with BRCA1/2 mutations (11 BRCA2
alone, 1 BRCA1 alone), 6 (50.0%) had a ≥50% reduction in PSA, with 5 (41.7%) achieving a confirmed PSA
response (figure 2B, table 3).
In cohort A2, among nine patients with baseline measurable disease and BRCA1/2 mutations (four BRCA2 alone,
three BRCA2 with other HRD gene mutations, one BRCA1
alone, and one BRCA1 with other HRD gene mutations),
three (33.3%) had a ≥30% reduction in target lesions
and all three achieved a confirmed objective response
(figure 3A, table 3). Among 13 PSA-evaluable patients
with BRCA1/2 mutations (9 BRCA2 alone, 3 BRCA2 with
other HRD gene mutations, and 1 BRCA1 with other
HRD gene mutations), all 13 (100.0%) had a ≥50%
reduction in PSA, with 11 (84.6%) achieving a confirmed
PSA response (figure 3B, table 3). Median rPFS and OS
for patients with BRCA1/2 mutations are shown in table 3
and were relatively consistent with median observed
for the overall HRD-positive subgroups (figure 1A–D).
Figures 2 and 3 also show that a small number of patients
8

had microsatellite instability-
high disease and/or were
carrying MSH2 and/or MSH6 structural rearrangements,
although there were too few patients to assess any associations with changes in tumor size or PSA.
Eighty-two of 88 patients in cohort A1 and 60 of 71 in
cohort A2 had available TMB data. As shown in online
supplemental table 5, clinical activity was observed regardless of TMB status. However, there were no consistent
trends in efficacy outcomes among subgroups of patients
with TMB at or above versus below the median (6.7 mutations per Mb).
Safety, cohorts A1 (postchemotherapy) and A2
(chemotherapy-naïve)
Any-
grade TRAEs occurred in 93.2% and 90.1% of
all treated patients in cohorts A1 and A2, respectively
(table 4). The most common any-grade treatment-related
events were nausea (40.9%), fatigue (33.0%), anemia
(26.1%), and decreased appetite (26.1%) in cohort A1,
and nausea (40.8%), anemia (32.4%), fatigue (28.2%),
and increased alanine aminotransferase (ALT; 28.2%)
in cohort A2. Grade 3–4 TRAEs occurred in 54.5% and
50.7% of patients, respectively, with the most common
events being anemia (20.5%) and neutropenia (10.2%)
Fizazi K, et al. J Immunother Cancer 2022;10:e004761. doi:10.1136/jitc-2022-004761
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Figure 3 Waterfall plots of maximum change from baseline in tumor size (A) and PSA (B) based on HRD-related genetic
mutations for cohort A2. *Patients with a measurable target lesion at baseline and at least one on-treatment tumor assessment;
one patient did not have available tumor change data. †Represents patients categorized as HRD-positive but with missing
information on the specific genetic mutation(s). ‡Patients with baseline PSA and at least one postbaseline PSA assessment.
Horizontal reference lines indicate a 30% reduction consistent with a PCWG3 response (A) or a 50% reduction consistent with
a PSA response (B). Open squares indicate truncation of percent change at +100%. +Symbol represents a confirmed objective
response; ▲ Symbol represents a confirmed PSA response. HRD, homologous recombination deficiency; NA, not available;
PCWG3, Prostate Cancer Clinical Trials Working Group 3; PSA, prostate-specific antigen.

in cohort A1 and anemia (14.1%) and increased ALT
(12.7%) in cohort A2.
Any-grade treatment-related serious AEs were reported
in 28.4% and 19.7% of patients in cohorts A1 and A2,
with grade 3–4 treatment-related serious AEs reported
in 27.3% and 18.3%, respectively (online supplemental
table 6). The most common grade 3–4 treatment-related
serious AEs were anemia in cohort A1 (6.8%), and
increased ALT and aspartate aminotransferase in cohort
A2 (2.8% each). Any-grade TRAEs led to discontinuation
of one or both study drugs in 27.3% and 23.9% of patients
in cohorts A1 and A2, respectively (online supplemental
table 7). The most common grade 3–4 events leading to
discontinuation were febrile neutropenia and neutropenia in cohort A1 (2.3% each) and anemia in cohort
A2 (4.2%).
grade
The most commonly reported individual any-
immune-mediated AE in both cohorts was hypothyroidism
(8.0% and 7.0% in cohorts A1 and A2, respectively;
online supplemental table 8). Hepatic immune-mediated
AEs comprised the most frequent grade 3–4 immune-
mediated events, reported in 5.7% of patients in cohort
A1 and 7.0% of patients in cohort A2.
Fizazi K, et al. J Immunother Cancer 2022;10:e004761. doi:10.1136/jitc-2022-004761

In cohort A1, one on-study death was considered related
to study treatment. Specifically, a patient with a preexisting meningioma had a stroke, for which a relationship
to rucaparib could not be excluded by the investigator,
after 28 days on rucaparib and two doses of nivolumab
and died 2 months later due to postthrombolysis hematoma. There were no treatment-related deaths in cohort
A2.

DISCUSSION
Based on the suboptimal efficacy of nivolumab monotherapy in unselected populations of patients with
mCRPC, the phase 2 CheckMate 9KD trial was designed to
investigate the hypothetical clinical benefits of combining
nivolumab with other anticancer treatments that could
potentially stimulate a more immune-responsive tumor
microenvironment, namely rucaparib, docetaxel, or
enzalutamide. Results for the cohort of patients treated
with nivolumab plus docetaxel (cohort B) have been
reported in a separate publication and showed encouraging clinical activity of this combination in men with
chemotherapy-naïve mCRPC.26 Here, we report results
9
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Table 3 Efficacy outcomes in patients with BRCA1/2 mutations in cohorts A1 and A2
Cohort A1
(postchemotherapy) (N=12)

Cohort A2
(chemotherapy-naïve) (N=15)

Objective response*
 Evaluable patients, n†

9‡

9

 Confirmed ORR (95% CI), %

33.3 (7.5 to 70.1)

33.3 (7.5 to 70.1)

0
3 (33.3)
4 (44.4)
1 (11.1)
1 (11.1)

0
3 (33.3)
5 (55.6)
1 (11.1)
0

 Evaluable patients, n¶

12

13

 Confirmed PSA50-RR (95% CI), %

41.7 (15.2 to 72.3)

84.6 (54.6 to 98.1)

 Evaluable patients**

12

15

 Median rPFS (95% CI), months
 Median OS (95% CI), months

5.6 (2.8 to 15.7)
15.2 (3.0 to not estimable)

10.9 (5.6 to 12.0)
20.2 (11.1 to not estimable)

 BOR, n (%)
 Complete response
 Partial response
 Stable disease
 Progressive disease
 Unable to determine
PSA response§

Survival outcomes

*Confirmed complete or partial response per PCWG3.
†Patients with measurable disease at baseline and BRCA1/2 mutations.
‡Includes one patient with measurable disease at baseline and a BRCA2 mutation, but with no on-treatment tumor assessment; this patient is
omitted from the associated waterfall plot (figure 2A).
§A decrease in PSA from baseline to the lowest postbaseline PSA result of ≥50%; a second consecutive value obtained at least 3 weeks later
was required for confirmation of PSA responses.
¶Patients with a baseline and at least one postbaseline PSA assessment and BRCA1/2 mutations.
**All treated patients with BRCA1/2 mutations.
BOR, best overall response; ORR, objective response rate; OS, overall survival; PCWG3, Prostate Cancer Clinical Trials Working Group 3;
PSA, prostate-specific antigen; PSA50-RR, PSA response rate; rPFS, radiographic progression-free survival.

from cohorts A1 and A2 of CheckMate 9KD, which
showed that the clinical antitumor activity of nivolumab
plus rucaparib was limited in the overall (unselected)
chemotherapy-
naïve and postchemotherapy mCRPC
cohorts, and that no new safety signals were observed with
the combination regimen.
Although nivolumab plus rucaparib had minimal clinical activity in the unselected mCRPC populations, noteworthy efficacy differences were observed when patients
were analyzed by HRD mutational status. Among patients
with HRD-positive tumors, encouraging response rates
and survival outcomes were observed, regardless of
whether the patients had received prior chemotherapy for
mCRPC. Moreover, despite small sample sizes, subgroups
of patients harboring BRCA1/2 mutations had further
improved objective and PSA response rates, although
survival outcomes in these subgroups were similar to
those reported for the overall HRD-positive subpopulations. In both cohorts, most patients carrying BRCA1/2
mutations had an alteration in the BRCA2 gene; as such,
any differences in the relative influence of BRCA1 versus
BRCA2 mutations on response to nivolumab plus rucaparib could not be determined from this patient population. Of note, in a prior study of the combination of
durvalumab and olaparib for mCRPC,4 most responders
10

to treatment carried BRCA mutations, and in a recent
study of pembrolizumab plus olaparib,30 patients with
mCRPC carrying BRCA mutations showed higher objective and PSA response rates versus those not carrying these
mutations, results that support the findings reported
here. These observations might be somewhat expected
as several studies have shown improved responses to
PARP inhibitor monotherapy in patients with mCRPC
and BRCA1/2 mutations compared with patients carrying
other DNA damage repair mutations and/or unselected
populations,17 19 31 32 and preliminary small-scale analyses
have suggested that patients carrying DNA damage repair
mutations (including in BRCA1/2 or ATM) are more
responsive to PD-1/PD-L1 checkpoint inhibitor therapy
than those without these mutations.10 15 16 Interestingly,
in some of the prior studies of PARP inhibitor monotherapy, PFS and/or OS were improved among patients
with BRCA mutations versus those with non-BRCA DNA
damage repair mutations31 32—an outcome that was not
seen in the CheckMate 9KD cohorts. It is unclear why
the higher response rates in patients with BRCA-positive
tumors versus the overall HRD-positive subpopulations
observed in our study did not translate into observable survival advantages. In contrast to the patients in
cohorts A1 and A2 with HRD-positive tumors, those with
Fizazi K, et al. J Immunother Cancer 2022;10:e004761. doi:10.1136/jitc-2022-004761
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Table 4 Treatment-related AEs in all treated patients in cohorts A1 and A2
Cohort A1
(postchemotherapy) (N=88)

Cohort A2
(chemotherapy-naïve) (N=71)

Treatment-related AEs, n (%)*

Any grade

Grade 3–4

Any grade

Grade 3–4

Any treatment-related AE
 Nausea

82 (93.2)
36 (40.9)

48 (54.5)
4 (4.5)

64 (90.1)
29 (40.8)

36 (50.7)
0

 Fatigue

29 (33.0)

5 (5.7)

20 (28.2)

2 (2.8)

 Anemia

23 (26.1)

18 (20.5)

23 (32.4)

10 (14.1)

 Decreased appetite

23 (26.1)

2 (2.3)

13 (18.3)

3 (4.2)

 Diarrhea

21 (23.9)

3 (3.4)

14 (19.7)

3 (4.2)

 Vomiting

20 (22.7)

2 (2.3)

13 (18.3)

1 (1.4)

 Asthenia

19 (21.6)

3 (3.4)

7 (9.9)

1 (1.4)

 Alanine aminotransferase increased

16 (18.2)

6 (6.8)

20 (28.2)

9 (12.7)

 Neutropenia

14 (15.9)

9 (10.2)

3 (4.2)

3 (4.2)

 Aspartate aminotransferase increased

13 (14.8)

2 (2.3)

18 (25.4)

5 (7.0)

 Dysgeusia

10 (11.4)

0

9 (12.7)

0

 Thrombocytopenia

9 (10.2)

4 (4.5)

6 (8.5)

2 (2.8)

 Pruritus

9 (10.2)

0

11 (15.5)

1 (1.4)

 Acute kidney injury

6 (6.8)

3 (3.4)

1 (1.4)

1 (1.4)

 Rash

6 (6.8)

1 (1.1)

8 (11.3)

1 (1.4)

 Blood alkaline phosphatase increased

5 (5.7)

3 (3.4)

3 (4.2)

0

 Leukopenia

4 (4.5)

3 (3.4)

1 (1.4)

0

 Blood creatinine increased

4 (4.5)

0

15 (21.1)

0

 Hepatoxicity

4 (4.5)

2 (2.3)

1 (1.4)

1 (1.4)

 Febrile neutropenia

3 (3.4)

3 (3.4)

0

0

 Muscular weakness

2 (2.3)

2 (2.3)

2 (2.8)

0

 Hepatitis

2 (2.3)

2 (2.3)

1 (1.4)

0

 Lymphopenia

2 (2.3)

2 (2.3)

1 (1.4)

1 (1.4)

 Gamma-glutamyl transferase increased

2 (2.3)

2 (2.3)

0

0

 Hypophosphatemia
 Neutrophil count decreased

1 (1.1)
0

1 (1.1)
0

4 (5.6)
3 (4.2)

3 (4.2)
2 (2.8)

*Includes individual any-grade treatment-related AEs reported between first dose of nivolumab plus rucaparib and 30 days after the last dose
of study drug and occurring in >10% of all treated patients and/or grade 3–4 treatment-related AEs reported between first dose of nivolumab
plus rucaparib and 30 days after the last dose of study drug and occurring in >2% of all treated patients in either cohort.
AE, adverse event.

HRD-negative tumors showed infrequent responses and
appear to derive limited benefit from the nivolumab plus
rucaparib combination.
As this trial did not include nivolumab and/or rucaparib monotherapy control arms, determining the contribution of each component to the observed outcomes is
challenging. In the TRITON2 trial of rucaparib monotherapy for postchemotherapy mCRPC, an investigator-
assessed ORR of 50.8%, a PSA50-
RR of 54.8%, and a
median investigator-
assessed rPFS of 8.5 months were
reported among patients with BRCA1/2 mutations,19
which might suggest, considering the findings from
cohort A1 in this study, that nivolumab contributes little
additional benefit over rucaparib alone. However, cross-
study comparisons should be treated cautiously due to
Fizazi K, et al. J Immunother Cancer 2022;10:e004761. doi:10.1136/jitc-2022-004761

the inherent influence of various factors (eg, study design
and methodology and/or population characteristics)
on the respective trial outcomes. For example, whereas
patients in TRITON2 had received only one prior taxane
regimen in the castration-resistant setting per the study
inclusion criteria,19 almost a third of the patients in
cohort A1 had received two prior taxane regimens for
mCRPC, a distinction that might have influenced the
clinical efficacy reported for each study. Data from the
ongoing TRITON3 trial (NCT02975934) might provide
a benchmark against which to further hypothesize on the
potential clinical benefits of dual PD-1/PD-L1 and PARP
inhibition in chemotherapy-naïve mCRPC populations.
Nevertheless, based on results from cohort A1 of CheckMate 9KD, along with the recent early discontinuation
11
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for futility of the KEYLYNK-010 trial of pembrolizumab
plus olaparib in postchemotherapy mCRPC,33 further
investigation of combination treatment with anti-PD-1/
PD-L1 immune checkpoint inhibitors plus PARP inhibitors in unselected mCRPC populations appears to be
unwarranted.
Although sample sizes were small, data from this trial
showed clinical activity of nivolumab plus rucaparib in
patients carrying non-BRCA HRD mutations. In the postchemotherapy setting (cohort A1), confirmed objective
and/or PSA responses were observed in patients with
mutations in ATM alone, CHEK2 alone, and both CHEK2
and FANCA. In the chemotherapy-naïve setting (cohort
A2), confirmed responses were observed in patients with
mutations in ATM or CHEK2 alone. This observation
aligns with data from other studies of PARP inhibitors
for mCRPC. For example, the TALAPRO-1 trial showed
objective and/or PSA responses to monotherapy with the
PARP inhibitor talazoparib in a small number of patients
with mCRPC carrying only ATM or PALB2 mutations.32
Likewise, the TRITON2 trial showed both objective and
PSA responses to rucaparib monotherapy in patients
with mCRPC and single ATM, FANCA, BRIP1, PALB2,
and RAD51B mutations, although cohorts of patients
carrying these mutations were very small.18 Interestingly,
in TRITON2, responders with CHEK2 mutations also
carried mutations in ATM or BRCA2, leading the authors
to suggest that CHEK2 alteration alone might not be
sufficient to render tumor cells responsive to rucaparib
monotherapy.18 As with the overall HRD-
positive and
BRCA-
positive populations, determining whether the
addition of nivolumab incrementally improves responses
rates over rucaparib alone in patients with non-
BRCA
HRD mutations is beyond the scope of the current study.
The role of TMB in antitumor responses to immune
checkpoint inhibitors among patients with mCRPC
remains uncertain, with some preliminary studies
suggesting a positive relationship with ‘high’ TMB,16
and others suggesting that ‘high’ TMB does not predict
improved response.34 35 Moreover, unlike in some other
tumor types, there is no established threshold for ‘high’
TMB in patients with mCRPC and no standardized methodology for assessing TMB (eg, whole exome sequencing
versus next-generation sequencing), further challenging
the interpretation of results from these preliminary
studies. Results from the current analyses did not demonstrate a clear association between ‘high’ or ‘low’ TMB
and efficacy with combined nivolumab plus rucaparib.
Additional prospective investigations would be required
to determine the influence of TMB on response to immunotherapy and whether that influence is maintained with
novel immunotherapy-based combination regimens.
The safety and tolerability profile of nivolumab plus
rucaparib was as anticipated based on prior studies of
the single agents in mCRPC or other tumors.18 19 36 37
Moreover, the types of TRAEs observed and their relative incidence was similar to that recently reported for
a study of pembrolizumab combined with olaparib in
12

docetaxel-pretreated mCRPC.38 Across both cohorts,
there was only one treatment-related death. Furthermore,
although this death was considered possibly related to
rucaparib treatment by the study investigator, the patient
had a preexisting condition (meningioma) that possibly
contributed to the sequence of events leading to the fatal
event.
In conclusion, the combination of nivolumab and
rucaparib showed clinical efficacy in patients with HRD-
positive chemotherapy-
naïve or postchemotherapy
mCRPC, particularly in those harboring BRCA1/2 mutations. Safety of the combination was as expected, with
no new signals identified. However, the modest activity
observed as compared with historic single-agent therapy,
the lack of study comparator arms, and the relatively short
follow-up for these cohorts prevent adequate assessment
of the clinical benefits of adding nivolumab to rucaparib.
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Supplemental Methods 1 Estimates of reference response rates for sample size determinations
Estimates of reference PSA and objective response rates for cohorts A1 and A2 were based on the
standard of care for the respective metastatic castration-resistant prostate cancer populations at the
time of protocol preparation.
For patients enrolled into cohort A1 (ie, those with 1–2 prior taxane-based regimens),
standard of care would have been second-line cabazitaxel for those with one prior taxane-based
regimen, and best supportive care for those with two prior taxane-based regimens. PSA and
objective response rate estimates for second-line cabazitaxel were 30% and 14%, respectively.
According to studies conducted in the postchemotherapy setting, patients receiving placebo
(assumed equivalent to best supportive care) had PSA and objective response rates of 2%–6% and
3%–4%, respectively (Scher HI, et al. N Engl J Med 2012;367:1187–97; de Bono JS, et al. N Engl J
Med 2011;364:1995–2005). On this basis, reference PSA and objective response rates for cohort A1
were 20% and 10%, respectively.
For patients enrolled into cohort A2 (ie, chemotherapy-naïve and having failed prior
abiraterone, enzalutamide, and/or apalutamide), standard of care would have been docetaxel
chemotherapy. Estimates of PSA and objective response rates for docetaxel were extrapolated from
the FIRSTANA clinical trial of docetaxel versus cabazitaxel as first-line therapy for mCRPC (Oudard
S, et al. J Clin Oncol 2017;35:3189–97). However, considering that (1) the administration of
docetaxel after one or more novel hormonal therapies might have less activity than in the pivotal trials
(Mezynski J, et al. Ann Oncol 2012;23:2943–47), (2) only ~3% of participants in the FIRSTANA trial
had received prior abiraterone or enzalutamide, and (3) all patients in cohort A2 had received prior
abiraterone, enzalutamide, and/or apalutamide, the estimates based on the FIRSTANA trial were
considered too optimistic. As such, the estimate of reference PSA response rate was modified based
on data from the COU-AA-302 post hoc analysis, in which post-abiraterone docetaxel treatment led
to a PSA response rate of 27% (de Bono JS, et al. Eur Urol 2017;71:656–64). A reference PSA
response rate of 47%, which is between those obtained in the FIRSTANA trial (68%) and
COU-AA-302 post hoc analysis (27%), was chosen. Since the COU-AA-302 post hoc analysis did not
report on objective responses, a reference objective response rate of 21% was chosen, taking into
account the response rates from the FIRSTANA trial (31%) and from a retrospective evaluation of the
activity of docetaxel in patients previously treated with abiraterone (11%; Mezynski J, et al. Ann Oncol
2012;23:2943–47).
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Supplemental Table 1 Patient disposition in cohorts A1 and A2
Cohort A1
(postchemotherapy)
(N=88)
4 (4.5)
1 (1.1)*
83 (94.3)

Cohort A2
(chemotherapy-naïve)
(N=71)
4 (5.6)
2 (2.8)†
65 (91.5)

On study treatment, n (%)
Completing study treatment, n (%)
Not completing study treatment, n (%)
Reasons for treatment discontinuation, n (%)
Disease progression
65 (73.9)
43 (60.6)
Study drug toxicity
9 (10.2)
8 (11.3)
Adverse event unrelated to study drug
4 (4.5)
4 (5.6)
Patient request to discontinue study drug
3 (3.4)
3 (4.2)
Death
1 (1.1)
1 (1.4)
Patient withdrew consent
1 (1.1)
0
Poor/non-compliance
0
1 (1.4)
Other
0
5 (7.0)
*Case represents a site data entry error; notification was received after database lock that the patient
discontinued treatment due to disease progression.
†One case represents a site data entry error; notification was received after database lock that the patient
discontinued treatment due to disease progression. The other case represents a protocol misinterpretation
where site investigators stopped treatment of both nivolumab and rucaparib after 2 years (the protocol
mandated that only nivolumab treatment should be stopped after a maximum of 2 years and rucaparib
treatment could continue beyond this point).

3

Fizazi K, et al. J Immunother Cancer 2022; 10:e004761. doi: 10.1136/jitc-2022-004761

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Supplemental Table 2 Treatment exposure in cohorts A1 and A2

Median duration of therapy (range), months
Relative dose intensity, n (%)
≥110%
90% to <110%
70% to <90%
50% to <70%
<50%
Median no. of doses (range)
Patients with dose delays, n (%)
Dose delays per patient, n (%)
0
1
2
3
≥4
Total no. of dose delays

Cohort A1
(postchemotherapy)
(N=88)
Nivolumab
Rucaparib
3.7 (0.0–17.8)
4.0 (0.3–17.9)

Cohort A2
(chemotherapy-naïve)
(N=71)
Nivolumab
Rucaparib
4.6 (0.0–23.2)
5.5 (0.0–30.9)

0
68 (77.3)
20 (22.7)
0
0

2 (2.3)
46 (52.3)
24 (27.3)
6 (6.8)
10 (11.4)

0
52 (73.2)
17 (23.9)
1 (1.4)
1 (1.4)

0
37 (52.1)
19 (26.8)
13 (18.3)
2 (2.8)

4.5 (1–19)
40 (45.5)

NA
7 (8.0)

6.0 (1–25)
34 (47.9)

NA
5 (7.0)

48 (54.5)
29 (33.0)
8 (9.1)
2 (2.3)
1 (1.1)

81 (92.0)
4 (4.5)
0
1 (1.1)
2 (2.3)

37 (52.1)
21 (29.6)
7 (9.9)
5 (7.0)
1 (1.4)

66 (93.0)
3 (4.2)
0
0
2 (2.8)

55

24

55

13

16 (29.1)
18 (32.7)
17 (30.9)
4 (7.3)

1 (7.7)
3 (23.1)
8 (61.5)
1 (7.7)

Length of dose delays, n (%)*
25 (45.5)
3 (12.5)
≤7 days
15 (27.3)
8 (33.3)
8 to ≤14 days
13 (23.6)
9 (37.5)
15 to ≤42 days
2 (3.6)
1 (4.2)
>42 days
*Displayed as a proportion of the total number of dose delays per study treatment.
NA, not applicable.
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Supplemental Table 3 Number of patients with target lesion and PSA changes by HRD gene mutation(s) in cohort A1
Target lesion change*

PSA change†
Confirmed
Confirmed

objective
Mutated gene(s)

n

Any reduction

≥30% reduction

response‡

n

Any reduction

≥50% reduction

PSA response§

ATM alone

9

7

2

1

13

7

1

1

BRCA2 alone

8

8

6

3

11

9

6

5

CDK12 alone

2

2

1

0

5

3

1

0

CHEK2 alone

2

2

1

0

5

3

2

1

BARD1 alone

2

2

0

0

2

1

0

0

ATM; CDK12

1

1

0

0

1

1

1

0

CHEK2; FANCA

1

1

1

1

2

1

1

1

FANCA alone

0

–

–

–

2

2

1

0

BRCA1 alone

0

–

–

–

1

0

0

0

*In patients with a measurable target lesion at baseline and at least one on-treatment tumor assessment.
†In patients with a baseline and at least one postbaseline PSA assessment.
‡Confirmed complete or partial response per PCWG3.
§A decrease in PSA from baseline to the lowest postbaseline PSA result of ≥50%; a second consecutive value obtained at least 3 weeks later was
required for confirmation of PSA responses.
HRD, homologous recombination deficiency; PCWG3, Prostate Cancer Clinical Trials Working Group 3; PSA, prostate-specific antigen.
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Supplemental Table 4 Number of patients with target lesion and PSA changes by HRD gene mutation(s) in cohort A2
Target lesion change*

PSA change†
Confirmed

Confirmed

objective

PSA

Mutated gene(s)

n

Any reduction

≥30% reduction

response‡

n

Any reduction

≥50% reduction

response§

BRCA2 alone

4

4

2

2

9

9

9

8

ATM alone

4

1

1

1

7

4

1

1

CDK12 alone

3

1

0

0

4

2

0

0

CHEK2 alone

2

2

1

1

2

1

1

1

NBN alone

1

1

0

0

2

0

0

0

BRCA1 alone

1

0

0

0

0

–

–

–

FANCA alone

0

–

–

–

1

0

0

0

BRCA2; ATM

1

1

0

0

1

1

1

1

BRCA1; FANCA

1

1

1

1

1

1

1

1

CDK12; CHEK2

1

1

0

0

1

1

0

0

BRCA2; ATM; CHEK2

1

1

0

0

1

1

1

1

BRCA2; CDK12; NBN

1

1

0

0

1

1

1

0

*In patients with a measurable target lesion at baseline and at least one on-treatment tumor assessment.
†In patients with a baseline and at least one postbaseline PSA assessment.
‡Confirmed complete or partial response per PCWG3.
§A decrease in PSA from baseline to the lowest postbaseline PSA result of ≥50%; a second consecutive value obtained at least 3 weeks later was
required for confirmation of PSA responses.
HRD, homologous recombination deficiency; PCWG3, Prostate Cancer Clinical Trials Working Group 3; PSA, prostate-specific antigen.

6

Fizazi K, et al. J Immunother Cancer 2022; 10:e004761. doi: 10.1136/jitc-2022-004761

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Supplemental Table 5 Efficacy outcomes based on TMB status (< median vs ≥ median*) in cohorts A1 and A2
Cohort A1 (postchemotherapy)

Cohort A2 (chemotherapy-naïve)

< Median

≥ Median

< Median

≥ Median

25

31

17

16

8.0 (1.0 to 26.0)

12.9 (3.6 to 29.8)

29.4 (10.3 to 56.0)

6.3 (0.2 to 30.2)

38

40

28

28

7.9 (1.7 to 21.4)

17.5 (7.3 to 32.8)

25.0 (10.7 to 44.9)

32.1 (15.9 to 52.4)

40

42

28

32

3.7 (2.1 to 5.7)

5.6 (3.5 to 6.8)

8.2 (5.6 to 11.0)

8.1 (3.8 to 11.1)

15.7 (10.6 to 21.6)

11.0 (7.8 to 15.2)

22.9 (15.7 to NE)

12.6 (8.2 to 20.2)

Objective response†
Evaluable patients, n‡
Confirmed ORR (95% CI), %
PSA response§
Evaluable patients, n¶
Confirmed PSA50-RR (95% CI), %
Survival outcomes
Evaluable patients, n**
Median rPFS (95% CI), months
Median OS (95% CI), months

*Median TMB (6.7 mutations per Mb) was based on all treated patients with available TMB data across all cohorts in the CheckMate 9KD trial.
†Confirmed complete or partial response per PCWG3.
‡Patients with measurable disease at baseline and available TMB data.
§A decrease in PSA from baseline to the lowest postbaseline PSA result of ≥50%; a second consecutive value obtained at least 3 weeks later was
required for confirmation of PSA responses.
¶Patients with a baseline and at least one postbaseline PSA assessment and available TMB data.
**All treated patients with available TMB data.
NE, not estimable; ORR, objective response rate; OS, overall survival; PCWG3, Prostate Cancer Clinical Trials Working Group 3; PSA, prostate-specific
antigen; PSA50-RR, PSA response rate; rPFS, radiographic progression-free survival; TMB, tumor mutational burden.
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Supplemental Table 6 Summary of treatment-related serious AEs* in cohorts A1 and A2
Cohort A1
Cohort A2
(postchemotherapy)
(chemotherapy-naïve)
(N=88)
(N=71)
Any grade
Grade 3–4
Any grade
Grade 3–4
Any treatment-related serious AE, n (%)
25 (28.4)
24 (27.3)
14 (19.7)
13 (18.3)
Anemia
6 (6.8)
6 (6.8)
1 (1.4)
1 (1.4)
Neutropenia
4 (4.5)
4 (4.5)
0
0
Acute kidney injury
4 (4.5)
3 (3.4)
1 (1.4)
1 (1.4)
Febrile neutropenia
3 (3.4)
3 (3.4)
0
0
Diarrhea
2 (2.3)
2 (2.3)
0
0
Fatigue
2 (2.3)
2 (2.3)
0
0
Hepatitis
2 (2.3)
2 (2.3)
0
0
Alanine aminotransferase increased
0
0
2 (2.8)
2 (2.8)
Aspartate aminotransferase increased
0
0
2 (2.8)
2 (2.8)
Autoimmune nephritis
0
0
2 (2.8)
1 (1.4)
*Includes individual any-grade treatment-related serious AEs reported between first dose of nivolumab plus rucaparib and 30 days after the last dose of
study drug and occurring in >2% of all treated patients in either cohort.
AE, adverse event.
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Supplemental Table 7 Summary of treatment-related AEs leading to discontinuation* in cohorts A1 and A2
Cohort A1
(postchemotherapy)
(N=88)
Any grade
Grade 3–4

Cohort A2
(chemotherapy-naïve)
(N=71)
Any grade
Grade 3–4

Any treatment-related AE leading to
24 (27.3)
19 (21.6)
17 (23.9)
11 (15.5)
discontinuation, n (%)
Febrile neutropenia
2 (2.3)
2 (2.3)
0
0
Neutropenia
2 (2.3)
2 (2.3)
1 (1.4)
1 (1.4)
Diarrhea
2 (2.3)
1 (1.1)
1 (1.4)
0
Hepatotoxicity
2 (2.3)
1 (1.1)
0
0
Decreased appetite
2 (2.3)
0
0
0
Nausea
2 (2.3)
0
0
0
Anemia
1 (1.1)
1 (1.1)
3 (4.2)
3 (4.2)
Alanine aminotransferase increased
1 (1.1)
1 (1.1)
3 (4.2)
2 (2.8)
Aspartate aminotransferase increased
0
0
2 (2.8)
2 (2.8)
*Represents a treatment-related AE that led to permanent discontinuation of nivolumab and/or rucaparib; includes individual any-grade
treatment-related AEs reported between first dose of nivolumab plus rucaparib and 30 days after the last dose of study drug that led to discontinuation
and occurred in >2% of all treated patients in either cohort.
AE, adverse event.
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Supplemental Table 8 Summary of immune-mediated AEs* in cohorts A1 and A2

n (%)

Cohort A1
(postchemotherapy)
(N=88)
Any grade
Grade 3–4

Cohort A2
(chemotherapy-naïve)
(N=71)
Any grade
Grade 3–4

Endocrine
Adrenal insufficiency
2 (2.3)
1 (1.1)
0
0
Hypothyroidism
7 (8.0)
0
5 (7.0)
1 (1.4)
0
1 (1.4)
0
Hyperthyroidism
2 (2.3)
0
1 (1.4)
0
Autoimmune thyroiditis
0
0
1 (1.4)
0
Diabetes mellitus
0
Gastrointestinal
3 (3.4)
1 (1.1)
4 (5.6)
2 (2.8)
Diarrhea
1 (1.1)
1 (1.1)
2 (2.8)
0
Colitis/colitis ulcerative
0
0
1 (1.1)
1 (1.1)
Immune-mediated enterocolitis
Hepatic
Hepatotoxicity
4 (4.5)
2 (2.3)
1 (1.4)
1 (1.4)
Hepatitis
2 (2.3)
2 (2.3)
1 (1.4)
0
3 (4.2)
ALT increased
1 (1.1)
1 (1.1)
3 (4.2)
0
Transaminases increased
1 (1.1)
0
1 (1.4)
1 (1.4)
0
AST increased
0
3 (4.2)
1 (1.4)
0
Autoimmune hepatitis
0
2 (2.8)
1 (1.4)
0
Drug-induced liver injury
0
1 (1.4)
1 (1.4)
0
Hyperbilirubinemia
0
1 (1.4)
Hypersensitivity
0
0
1 (1.4)
1 (1.4)
Hypersensitivity
Pulmonary
1 (1.1)
0
2 (2.8)
0
Pneumonitis
Renal
1 (1.1)
1 (1.1)
0
0
Renal failure
1 (1.1)
0
0
0
Tubulointerstitial nephritis
Autoimmune nephritis
0
0
2 (2.8)
1 (1.4)
Immune-mediated nephritis
0
1 (1.4)
1 (1.4)
0
Skin
Rash
5 (5.7)
2 (2.3)
4 (5.6)
1 (1.4)
Rash pustular
0
0
1 (1.4)
0
*Includes immune-mediated AEs reported between first dose of nivolumab plus rucaparib and 100 days after
the last dose of study drug and occurring in >1% of all treated patients. Endocrine events listed represent all
reported immune-mediated endocrine AEs; non-endocrine events listed are those resulting in initiation of
immune-modulating medication.
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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Supplemental Figure 1 Oncoprints for HRD gene mutations in all treated patients in cohorts A1 (A; N=88) and A2 (B; N=71)
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*Includes one patient with mutations in ATM and CDK12.
†Includes one patient with mutations in CHEK2 and FANCA.
‡Includes one patient with mutations in BRCA2, ATM, and CHEK2; one with mutations in BRCA2 and ATM; and one with mutations in BRCA2, CDK12, and NBN.
§Includes one patient with mutations in BRCA2, ATM, and CHEK2, and one patient with mutations in BRCA2 and ATM.
¶Includes one patient with mutations in BRCA2, CDK12, and NBN and one patient with mutations in CDK12 and CHEK2.
**Includes one patient with mutations in BRCA2, ATM, and CHEK2 and one patient with mutations in CDK12 and CHEK2.
††Includes one patient with mutations in BRCA2, CDK12, and NBN.
‡‡Includes one patient with mutations in BRCA1 and FANCA.
CNA, copy number alteration.
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